Retatrutide (RETA-3) 20 mg
Original release: 25 September 2026
All analyses
ASL-2026-000742Original release: 25 September 2026
| ANALYSIS | METHOD | RESULT | SPECIFICATION | VERDICT |
|---|---|---|---|---|
| Identity | LC-MS (ESI+) | Conforms - identity confirmed | Consistent with reference | PASS |
| Purity | RP-HPLC-UV - area normalisation | 99.1% | ≥95.0% | PASS |
| Net content | Quantitative HPLC vs reference standard | 20.8 mg / vial (104.0% of label) | 20 mg ± 10% | PASS |
| Bacterial endotoxins | LAL - USP <85> | PASS | Within specification | PASS |
| Heavy metals | ICP-MS | PASS | ICH Q3D limits | PASS |
Notes
Results apply only to the vial submitted, as received, on the dates stated. Purity is reported as area percent; net content is the measured amount per vial against the labelled 20 mg. Endotoxins and heavy metals are reported as PASS in the supplied COA. Numerical results or individual analyte concentrations were not provided. This is a reformatted copy and adds no analytical determination, raw chromatogram, or analyst signature.
Scope and limitations
Results apply only to the submitted sample on the stated dates. They do not establish the status of another vial, lot, batch, or product. This is not a marketing authorisation, health product licence, DIN, NPN, FDA clearance, or approval, and makes no statement of safety, efficacy, or fitness for any purpose. Research and quality-control use only. Accreditation status in the source: ISO/IEC 17025:2017 - in progress.
Source report ASL-2026-000742; received 21 September 2026; date of analysis 24 September 2026; original release 25 September 2026. Reformatted from the supplied source COA. No new test result or signature is represented.